These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. Łojko D; Rybakowski JK J Affect Disord; 2007 Nov; 103(1-3):253-6. PubMed ID: 17289154 [TBL] [Abstract][Full Text] [Related]
24. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. Corya SA; Perlis RH; Keck PE; Lin DY; Case MG; Williamson DJ; Tohen MF J Clin Psychiatry; 2006 May; 67(5):798-806. PubMed ID: 16841630 [TBL] [Abstract][Full Text] [Related]
25. Mania and tramadol-fluoxetine combination. Gonzalez-Pinto A; Imaz H; De Heredia JL; Gutierrez M; Micó JA Am J Psychiatry; 2001 Jun; 158(6):964-5. PubMed ID: 11384912 [No Abstract] [Full Text] [Related]
26. Dose-dependent seizure activity associated with fluoxetine therapy. Oke A; Adhiyaman V; Aziz K; Ross A QJM; 2001 Feb; 94(2):113-4. PubMed ID: 11181988 [No Abstract] [Full Text] [Related]
27. [Pollakiuria and micturition syndrome related to fluoxetine]. Sancho A; Martínez-Mir I; Palop V Med Clin (Barc); 1995 Nov; 105(15):598-9. PubMed ID: 7500682 [No Abstract] [Full Text] [Related]
31. Efficacy and safety of fluoxetine monotherapy in bipolar depression: a systematic review. Martinotti G; Sepede G; Signorelli M; Aguglia E; Di Giannantonio M Expert Opin Pharmacother; 2013 Jun; 14(8):1065-75. PubMed ID: 23527943 [TBL] [Abstract][Full Text] [Related]
32. [Long QT syndrome due to Fluoxetine]. Canet Fajas C; Urieta González L; Ibañez Pérez de Viñaspre JA Semergen; 2018; 44(1):66-68. PubMed ID: 28851566 [No Abstract] [Full Text] [Related]
33. Serotonin syndrome in the deployed setting. Lawyer TI; Jensen J; Welton RS Mil Med; 2010 Dec; 175(12):950-2. PubMed ID: 21265300 [TBL] [Abstract][Full Text] [Related]
34. Tactile hallucinations with fluoxetine and methylphenidate. Arora GS; Arora HK; Sidhu J; Najjar F J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):360-1. PubMed ID: 25007312 [No Abstract] [Full Text] [Related]
35. Treatment of bipolar depression: a survey of Canadian psychiatrists. Sharma V; Mazmanian DS; Persad E; Kueneman KM Can J Psychiatry; 1997 Apr; 42(3):298-302. PubMed ID: 9114946 [TBL] [Abstract][Full Text] [Related]
36. Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. Hansen L J Psychopharmacol; 2003 Dec; 17(4):451-2. PubMed ID: 14870959 [TBL] [Abstract][Full Text] [Related]
37. Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline. Speiser Z; Fine T; Litinetsky L; Eliash S; Blaugrund E; Cohen S J Neural Transm (Vienna); 2008; 115(1):107-16. PubMed ID: 17823767 [TBL] [Abstract][Full Text] [Related]
38. Rational polypharmacy in the bipolar affective disorders. Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735 [TBL] [Abstract][Full Text] [Related]
39. A dispensing error resulting in possible fluoxetine overdose and subsequent discontinuation syndrome in a child. Velez LI; Feng SY; Neerman MF Clin Pediatr (Phila); 2010 Nov; 49(11):1072-4. PubMed ID: 20522613 [No Abstract] [Full Text] [Related]
40. Co-administration of fluoxetine and sumatriptan: the Canadian experience. Joffe RT; Sokolov ST Acta Psychiatr Scand; 1997 Jun; 95(6):551-2. PubMed ID: 9242852 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]